4DMedical (ASX:4DX) said medical device firm Olympus launched its SeleCT Screening population-level emphysema screening program using the 4DMedical's lung density analysis technology, according to a Wednesday Australian bourse filing.
The solution reviews existing computed tomography (CT) scans to identify patients with advanced emphysema who may be candidates for bronchoscopic lung volume reduction.
The program established Olympus as a key partner and scaled 4DMedical's lung analysis technology across major US health systems, the filing added.
4DMedical's shares fell 3% in recent trading on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。